Dimensional Fund Advisors Portfolio holdings
Dimensional Fund Advisors (DFA), founded in 1981 by David Booth and Rex Sinquefield and headquartered in Austin, Texas, is an investment management firm renowned for its evidence-based, low-cost approach to investing, grounded in academic research from Nobel laureates like Eugene Fama and Kenneth French. Managing hundreds of billions in assets, DFA focuses on systematic, passive strategies that tilt toward factors like small-cap, value, and profitability stocks, primarily through mutual funds and institutional portfolios rather than retail brokerage services. The firm’s philosophy eschews market timing and stock picking, instead emphasizing diversification and efficient market exposure, often requiring investors to access its funds through approved financial advisors. With a global presence and a reputation for disciplined, data-driven investing, DFA has carved a unique niche in the industry, blending academic rigor with practical application.
Top Buys
| 1 |
NVIDIA
NVDA
|
$2.08B |
| 2 |
Microsoft
MSFT
|
$699M |
| 3 |
Exxon Mobil
XOM
|
$614M |
| 4 |
Apple
AAPL
|
$587M |
| 5 |
UnitedHealth
UNH
|
$448M |
Top Sells
| 1 |
Broadcom
AVGO
|
$1.1B |
| 2 |
PXD
Pioneer Natural Resource Co.
PXD
|
$477M |
| 3 |
GE Aerospace
GE
|
$375M |
| 4 |
AEL
American Equity Investment Life Holding Company
AEL
|
$271M |
| 5 |
Applied Materials
AMAT
|
$209M |
Sector Composition
| 1 | Technology | 20.72% |
| 2 | Financials | 16.94% |
| 3 | Industrials | 12.29% |
| 4 | Consumer Discretionary | 10.5% |
| 5 | Healthcare | 10% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
3001
SIFCO Industries
SIF
$43.8M
| $596K | ﹤0.01% |
192,377
| – | – |
|
3002
scPharmaceuticals
SCPH
$299M
| $588K | ﹤0.01% |
135,080
-31,136
| -19% | -$135K |
|
|
API
3003
Agora
API
$310M
| $585K | ﹤0.01% |
275,866
+52,432
| +23% | +$111K |
|
3004
Urban One Class A
UONE
$73.5M
| $577K | ﹤0.01% |
289,965
-57,784
| -17% | -$115K |
|
3005
Airgain
AIRG
$52M
| $577K | ﹤0.01% |
95,528
-44,359
| -32% | -$268K |
|
3006
Monte Rosa Therapeutics
GLUE
$305M
| $575K | ﹤0.01% |
153,758
+81,083
| +112% | +$303K |
|
3007
American Shared Hospital Services
AMS
$16.3M
| $574K | ﹤0.01% |
179,637
+8,436
| +5% | +$27K |
|
3008
Ramaco Resources Class B
METCB
$1.05B
| $574K | ﹤0.01% |
54,092
-41
| -0.1% | -$435 |
|
3009
First Capital
FCAP
$145M
| $564K | ﹤0.01% |
18,531
-2,543
| -12% | -$77.4K |
|
3010
Savara
SVRA
$643M
| $557K | ﹤0.01% |
138,211
| – | – |
|
3011
Sturm, Ruger & Co
RGR
$572M
| $552K | ﹤0.01% |
+13,265
| New | +$552K |
|
3012
Cricut
CRCT
$1.26B
| $552K | ﹤0.01% |
92,139
+63,116
| +217% | +$378K |
|
3013
Outset Medical
OM
$249M
| $548K | ﹤0.01% |
9,486
-2,863
| -23% | -$165K |
|
3014
LGL Group
LGL
$35.7M
| $547K | ﹤0.01% |
101,906
| – | – |
|
3015
Kingstone Companies
KINS
$194M
| $546K | ﹤0.01% |
109,172
+7,320
| +7% | +$36.6K |
|
3016
SkyWater Technology
SKYT
$491M
| $544K | ﹤0.01% |
71,151
| – | – |
|
|
VBNK
3017
VersaBank
VBNK
$389M
| $540K | ﹤0.01% |
50,038
+15,462
| +45% | +$167K |
|
3018
AbCellera Biologics
ABCL
$1.26B
| $532K | ﹤0.01% |
179,882
+1,325
| +0.7% | +$3.92K |
|
3019
Xoma
XOMA
$426M
| $531K | ﹤0.01% |
22,414
-3,102
| -12% | -$73.5K |
|
3020
Sight Sciences
SGHT
$193M
| $524K | ﹤0.01% |
78,632
-5,234
| -6% | -$34.9K |
|
|
CLPR
3021
Clipper Realty
CLPR
$71.2M
| $518K | ﹤0.01% |
143,645
-3,571
| -2% | -$12.9K |
|
3022
SWK Holdings
SWKH
$178M
| $511K | ﹤0.01% |
37,998
+17,532
| +86% | +$236K |
|
3023
Dianthus Therapeutics
DNTH
$853M
| $510K | ﹤0.01% |
19,726
-2,002
| -9% | -$51.7K |
|
3024
NovoCure
NVCR
$1.37B
| $509K | ﹤0.01% |
29,664
-785
| -3% | -$13.5K |
|
|
FGNX
3025
Fundamental Global
FGNX
$12.8M
| $508K | ﹤0.01% |
21,433
-5,422
| -20% | -$128K |
|